Tessera
Folgen

Eslam Katab

@eslamkatab.bsky.social

Global Clinical Development Manager @ Sandoz 2021’s MIT innovators under 35 Pharmacist with PhD In Experimental Medicine @TU Munich

3 Posts127 Follower552 Folgt
Jon Lim, FRCP PhD@drjonlim.bsky.social · 2y ago

📢 Shout out to @giampazolias.bsky.social - we made it to the 2️⃣0️⃣2️⃣4️⃣ year-end “Crick Five Stories”. @crick.ac.uk #CancerImmunology #HostMicrobiome 🔗 Check out our original paper #OpenAccess: www.science.org/doi/10.1126/...

Vitamin D regulates microbiome-dependent cancer immunity

A role for vitamin D in immune modulation and in cancer has been suggested. In this work, we report that mice with increased availability of vitamin D display greater immune-dependent resistance to tr...

science.org

Post nicht verfügbar.
Jon Lim, FRCP PhD@drjonlim.bsky.social · 2y ago

🔭 What’s in store next for cell therapy for solid tumours? 2024 has been seismic with the @fda.gov approval of Lifileucel (melanoma) & Afami-cel (sarcoma). Check out this outlook piece out today in Nat Cancer by Kishton & Restifo 👇 @natureportfolio.bsky.social www.nature.com/articles/s43...

T cells lead the charge against solid tumors - Nature Cancer

In 2024, two groundbreaking approvals from the US Food and Drug Administration for T cell-based therapies that target solid tumors were achieved. Lifileucel, a polyclonal tumor-infiltrating lymphocyte...

nature.com

Stephen Liu@stephenvliu.bsky.social · 2y ago

Development of two next gen IO molecules has been discontinued. Vibostolimab (anti #TIGIT) and favezelimab (anti LAG3) programs both being shuttered. Development in this space has been significantly hampered by the lack of predictive biomarkers. www.merck.com/news/merck-p...

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab - Merck.com

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezeli...

merck.com

Eslam Katab@eslamkatab.bsky.social · 2y ago

Longer PFS and lower high grade AEs in Nivolumab+AVD vs brentuximab vedotin + AVD in newly diagnosed stage III or IV Hodgkin lymphoma patients www.nejm.org/doi/full/10.... #Immunotherapy #Nivolumab #Hodgkin_lymphoma

Nivolumab+AVD improves progression-free survival in advanced-stage Hodgkin lymphoma | 2 Minute Medicine

1. This randomized controlled trial found that in patients with newly diagnosed stage III or IV Hodgkin lymphoma, treatment with nivolumab + AVD (N+AVD) led to longer progression-free survival compare...

2minutemedicine.com

Eslam Katab@eslamkatab.bsky.social · 2y ago

A Phase I trial with GD2-targeted CAR T-cells shows promising results in agressive pediatric gliomas: ✅ Outcomes: Tumor reduction: 52–100% in 4 patients. Durable response: 30+ months in 1 patient. Neurological gains in 9/11 patients. ✅ Safety: ICV delivery = fewer toxicities vs. IV. #NeuroOncology

Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas - Nature

We evaluated the use of chimeric antigen receptor-modified T cells targeting GD2 (GD2-CART) for H3K27M+ diffuse midline glioma (DMG), finding that intravenous administration of GD2-CART, followed by i...

nature.com